AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24751323
Drug: Dihydrotestosterone (DHT)
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrotestosterone (DHT) 70 mg daily transdermal treatment
Trial: 8732120
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus radiation and IL‐2
Trial: 26795622
Drug: 0.05 %
RxNorm normalized name: CTx4 0.05 % Oral Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 % chlorhexidine digluconate (CHX)/herbal extract combination
Trial: 26795622
Drug: 0.1 %
RxNorm normalized name: carbon monoxide 0.1 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 % chlorhexidine solution
Trial: 22378155
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral lisinopril 2.5 mg (n = 17)
Trial: 22378155
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral placebo (n = 16)
Trial: 21076717
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day folic acid supplementation
Trial: 15886721
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/day for 12 weeks
Trial: 15886721
Drug: Haloperidol 20
RxNorm normalized name: haloperidol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 20 mg/day for 12 weeks
Trial: 10834778
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia with morphine sulfate (PCA)
Trial: 9105543
Drug: Meloxicam (7.5-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (7.5-30 mg)
Trial: 9105543
Drug: Meloxicam (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (various formulations)
Trial: 8371127
Drug: Clarithromycin suspension
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin suspension 7.5 mg/kg bodyweight twice daily
Trial: 8371127
Drug: Amoxycillin suspension
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin suspension 125 mg (bodyweight < 25 kg) or 250 mg (bodyweight ≥ 25 kg) three times a day
Trial: 3524488
Drug: Papaverine 60
RxNorm normalized name: papaverine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine 60 mg added to cold cardioplegia
Trial: 26282062
Drug: Maxacalcitol topical
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maxacalcitol topical ointment (22‐oxacalcitriol [OCT]), applied twice daily for 8 weeks
Trial: 26282062
Drug: Maxacalcitol topical
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maxacalcitol topical ointment (22‐oxacalcitriol [OCT])
Trial: 22307384
Drug: Teriflunomide 7
RxNorm normalized name: teriflunomide 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide 7 mg/day
Trial: 30729028
Drug: Teriflunomide 14
RxNorm normalized name: teriflunomide 14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide 14 mg/day
Trial: 22307384
Drug: Teriflunomide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide (both doses)
Trial: 20609215
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion (single day or five days, eight hours)
Trial: 18048820
Drug: Topical tazarotene
RxNorm normalized name: tazarotene Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tazarotene
Trial: 16211753
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg orally, twice daily for 2.5 days)
Trial: 7726484
Drug: Intranasal pirodavir
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal pirodavir (2 mg per treatment) six times daily for 5 days
Trial: 7726484
Drug: Intranasal pirodavir
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal pirodavir
Trial: 31665059
Drug: DISE-assisted titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DISE-assisted titration
Trial: 31665059
Drug: Conventional subjective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional subjective titration method
Trial: 28893675
Drug: Non-opioid medication
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid medication therapy
Trial: 26496285
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and Root Planing (SRP) + Low-Level Laser Therapy (LLLT)
Trial: 19590518
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no injection of TA)
Trial: 16328318
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (5 mg, 10 mg, 20 mg, 30 mg bid)
Trial: 2193560
Drug: Adenosine 3
RxNorm normalized name: adenosine 3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 3 mg
Trial: 2193560
Drug: Adenosine 6
RxNorm normalized name: adenosine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 6 mg
Trial: 2193560
Drug: Adenosine 9
RxNorm normalized name: adenosine 90 MG in 30 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 9 mg
Trial: 2193560
Drug: Adenosine 6
RxNorm normalized name: adenosine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 6 mg followed by 12 mg if necessary
Trial: 2193560
Drug: Verapamil 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 5 mg followed by 7.5 mg if necessary
Trial: 6818806
Drug: 2-4 mg
RxNorm normalized name: hexylresorcinol 2.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-4 mg of micronized oestradiol-17 beta taken orally
Trial: 6818806
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of oestradiol-17 beta applied cutaneously
Trial: 6818806
Drug: Doubling of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling of the oral dose from 2 mg to 4 mg
Trial: 28225996
Drug: Diacerein as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein as an add-on to metformin
Trial: 25701295
Drug: Color-coded prefilled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Color-coded prefilled medication syringes
Trial: 25701295
Drug: Conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medication administration methods
Trial: 19717184
Drug: Otamixaban 0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban 0.035 mg/kg/h
Trial: 19717184
Drug: Otamixaban 0.070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban 0.070 mg/kg/h
Trial: 19717184
Drug: Otamixaban 0.105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban 0.105 mg/kg/h
Trial: 19717184
Drug: Otamixaban 0.140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban 0.140 mg/kg/h
Trial: 19717184
Drug: Otamixaban 0.175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban 0.175 mg/kg/h
Trial: 19717184
Drug: Control (unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (unfractionated heparin + eptifibatide)
Trial: 15942583
Drug: Bivalirudin (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (bolus of 50 mg in priming solution, 1.0 mg/kg for the patient, followed by an infusion of 2.5 mg . kg(‐1) . h(‐1) until 15 minutes before the conclusion of cardiopulmonary bypass)
Trial: 3556133
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravenous and oral Pentoxifylline with walk training
Trial: 12036640
Drug: Intracameral cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral cefuroxime 1 mg
Trial: 12036640
Drug: Control (nonadministration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (nonadministration of intracameral antibiotic prophylaxis)
Trial: 24560365
Drug: Multi-drug resistance
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug resistance (MDR) identified
Trial: 22366293
Drug: Insulin regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin regimen A
Trial: 22366293
Drug: Insulin regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin regimen B
Trial: 20369095
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (bar) - splinted mini-implants inserted using a prefabricated stainless steel guide
Trial: 20369095
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (ball) - splinted mini-implants placed without a guide
Trial: 18380825
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of i.v. furosemide
Trial: 18380825
Drug: Oral fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluids only (control)
Trial: 16280073
Drug: Menopur (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menopur (subcutaneous, SC)
Trial: 16280073
Drug: Repronex (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repronex (subcutaneous, SC)
Trial: 12371576
Drug: Extended Services
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended Services Intervention (ESI) - monthly phone contacts and referral information as needed.
Trial: 7055527
Drug: Diazepam 20
RxNorm normalized name: diazePAM 20 mg rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 20 mg (male) / Diazepam 10 mg (female) via Z-track injection technique
Trial: 7055527
Drug: Hydroxyzine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 100 mg i.m.
Trial: 7055527
Drug: Diazepam via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam via Z-track injection technique
Trial: 7055527
Drug: Diazepam via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam via other injection techniques (not specified)
Trial: 25153538
Drug: Alectinib (300-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib (300-900 mg twice a day)
Trial: 25153538
Drug: Alectinib (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib (300-600 mg twice a day)
Trial: 25153538
Drug: Alectinib (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib (900 mg twice a day)
Trial: 25153538
Drug: Alectinib (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib (not specified dose)
Trial: 20933178
Drug: Atomoxetine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (1.2 mg/kg per day, reached at 3 weeks)
Trial: 15866769
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for elevated blood lead concentrations (20-44 microg/dL)
Trial: 9728588
Drug: Gemcitabine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine with concurrent radiation therapy
Trial: 9728588
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and vinblastine as induction chemotherapy
Trial: 23596815
Drug: Periplaneta americana
RxNorm normalized name: PERIPLANETA AMERICANA
DrugBank: Periplaneta americana (DB10417)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periplaneta americana extract plus conventional medication for sepsis
Trial: 21312348
Drug: Multidisciplinary team
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidisciplinary team care program (12 weeks, 1 day per week; individual treatments, group exercises, and group education)
Trial: 30574797
Drug: HTX-019 130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-019 130 mg via 2-min injection (9 ml/min)
Trial: 30574797
Drug: HTX-019 130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-019 130 mg via 30-min infusion (296 ml/h)
Trial: 30574797
Drug: HTX-019 130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-019 130 mg via injection
Trial: 30574797
Drug: HTX-019 130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-019 130 mg via infusion
Trial: 24888810
Drug: Figitumumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (AUC 6 mg · min/mL)
Trial: 23082142
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists and GnRH antagonists
Trial: 19923505
Drug: Morphine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine IV 20 microg x kg(‐1) x h(‐1)
Trial: 19923505
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 0.1 mL x kg(‐1) x h(‐1) via FIC catheter
Trial: 10215751
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 0.6 IU
Trial: 10215751
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 1.2 IU
Trial: 10215751
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 1.8 IU
Trial: 10215751
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of recombinant human growth hormone (rhGH) at a dose of 1 IU
Trial: 1881996
Drug: Nicotine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (2 mg gum)
Trial: 1881996
Drug: Alcohol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (30 g)
Trial: 6219455
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (oral administration)
Trial: 6219455
Drug: Orchiectomy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orchiectomy without additional therapy (observation)
Trial: 30201054
Drug: Financial incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial incentive of €30 a month for 12 months for medication adherence.
Trial: 25266289
Drug: MK-5172 (100-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5172 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV)
Trial: 25266289
Drug: MK-5172 100
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5172 100 mg arm
Trial: 25266289
Drug: MK-5172 200
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5172 200 mg group
Trial: 20473064
Drug: Low-dose olanzapine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose olanzapine (1 mg/d)
Trial: 20473064
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (haloperidol 10-20 mg/d or medium-high dose olanzapine 7.5-17.5 mg/d)
Trial: 6476835
Drug: Etoposide (NK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (NK 171) intravenously at a dose of 100‐130 mg/m2/day for five days
Trial: 6476835
Drug: Etoposide (NK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (NK 171) orally at a dose of 130‐170 mg/m2/day for five days
Trial: 25293882
Drug: Niaspan FCT™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niaspan FCT™ (extended-release niacin)
Trial: 16142294
Drug: Cell therapy
RxNorm normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell therapy (cell suspension from immature nervous and hemopoietic tissues)
Trial: 30414855
Drug: ZPL-3893787 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPL-3893787 (30 mg once-daily oral therapy)
Trial: 24331269
Drug: Sublingual hyoscyamine
RxNorm normalized name: hyoscyamine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual hyoscyamine sulfate
Trial: 17974032
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate (1500 mg/day)
Trial: 17974032
Drug: Reparagen (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reparagen (1800 mg/day)
Trial: 15162947
Drug: High-dose phenobarbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose phenobarbital therapy (40 mg/kg during the first 60 min after birth)
Trial: 15162947
Drug: Conventional doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional doses of phenobarbital (only if clinical evidence of seizures)
Trial: 9389827
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 mg/d)
Trial: 9389827
Drug: Standard hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hormone replacement without aspirin (Control)
Trial: 7894214
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte alpha-interferon cream (2 x 10(6) IU/g) applied thrice a day for 3 consecutive days (group A) or 4 consecutive days (group B) per week, for a maximum of 4 weeks.
Trial: 7894214
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied in the same manner as the active treatment.
Trial: 28957728
Drug: Nicotine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (4 mg) in participants with greater nicotine dependence
Trial: 24042066
Drug: Lysine clonixinate
RxNorm normalized name: lysine clonixinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine clonixinate plus tramadol (LC 125 mg + T 25 mg)
Trial: 24042066
Drug: Tramadol (T)
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol (T) alone (50 mg)
Trial: 21034646
Drug: Pulmonary artery
RxNorm normalized name: Pulmonary artery blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary artery perfusion with hypothermic HTK solution
Trial: 15755850
Drug: Metformin (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (425 mg/d) for 6 months in SGA-PP girls
Trial: 15755850
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH, 60 mug/kg/d) in SGA-SS children
Trial: 11916785
Drug: GAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAN block with 2 mL of 0.25% bupivacaine with epinephrine (1:200,000) and a sham IV injection of 2 mL of saline solution
Trial: 11916785
Drug: GAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAN block with 2 mL of 0.25% bupivacaine with epinephrine (1:200,000)
Trial: 11916785
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine sulfate (0.1 mg/kg diluted to 2 mL)
Trial: 8682014
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg daily for 2 weeks, then 200 mg daily for 2 years
Trial: 2676908
Drug: Ibuprofen (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (initial dose 800 mg, additional 400 mg as needed)
Trial: 322082
Drug: Nitrofurantoin macrocrystals
RxNorm normalized name: Nitrofurantoin Macrocrystals
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin macrocrystals (1.2 to 2.4 mg/kg/day)
Trial: 23332236
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg etanercept plus methotrexate
Trial: 23332236
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg etanercept plus methotrexate
Trial: 19468948
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids supplementation (1.3 g daily for 6 weeks)
Trial: 18041889
Drug: Abatacept with
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept with TNF-alpha inhibitors
Trial: 4915361
Drug: Bromhexine 16
RxNorm normalized name: bromhexine 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine 16 mg thrice daily for 11 days
Trial: 25833983
Drug: Casein (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein (60 g daily)
Trial: 25833983
Drug: High or
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High or low MC-SFA content (63 g milk fat daily)